TW202339732A - 投予血紅素調節劑的方法 - Google Patents

投予血紅素調節劑的方法 Download PDF

Info

Publication number
TW202339732A
TW202339732A TW111147489A TW111147489A TW202339732A TW 202339732 A TW202339732 A TW 202339732A TW 111147489 A TW111147489 A TW 111147489A TW 111147489 A TW111147489 A TW 111147489A TW 202339732 A TW202339732 A TW 202339732A
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
dose
approximately
Prior art date
Application number
TW111147489A
Other languages
English (en)
Chinese (zh)
Inventor
艾琳 巴斯
肯 杜欽
卡拉 華盛頓
亞瑟 羅
Original Assignee
美商全球血液治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商全球血液治療公司 filed Critical 美商全球血液治療公司
Publication of TW202339732A publication Critical patent/TW202339732A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW111147489A 2021-12-10 2022-12-09 投予血紅素調節劑的方法 TW202339732A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202163288377P 2021-12-10 2021-12-10
US63/288,377 2021-12-10
US202263421524P 2022-11-01 2022-11-01
US63/421,524 2022-11-01
US202263429376P 2022-12-01 2022-12-01
US63/429,376 2022-12-01

Publications (1)

Publication Number Publication Date
TW202339732A true TW202339732A (zh) 2023-10-16

Family

ID=85108880

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111147489A TW202339732A (zh) 2021-12-10 2022-12-09 投予血紅素調節劑的方法

Country Status (10)

Country Link
US (1) US20250041312A1 (https=)
EP (1) EP4444285A1 (https=)
JP (1) JP2024545496A (https=)
KR (1) KR20240116826A (https=)
AU (1) AU2022408097B2 (https=)
CA (1) CA3241881A1 (https=)
IL (1) IL312835A (https=)
MX (1) MX2024007064A (https=)
TW (1) TW202339732A (https=)
WO (1) WO2023107697A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4727555A1 (en) * 2023-06-13 2026-04-22 Global Blood Therapeutics, Inc. (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
PT3880654T (pt) * 2018-11-19 2022-04-08 Global Blood Therapeutics Inc Compostos de 2-formil-3-hidroxifeniloximetil capazes de modular hemoglobina
EP4337659A1 (en) * 2021-05-14 2024-03-20 Global Blood Therapeutics, Inc. Solid forms of a modulator of hemoglobin

Also Published As

Publication number Publication date
AU2022408097B2 (en) 2026-03-12
KR20240116826A (ko) 2024-07-30
US20250041312A1 (en) 2025-02-06
CA3241881A1 (en) 2023-06-15
EP4444285A1 (en) 2024-10-16
MX2024007064A (es) 2024-06-20
AU2022408097A1 (en) 2024-05-30
IL312835A (en) 2024-07-01
JP2024545496A (ja) 2024-12-09
WO2023107697A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
US11052073B1 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
KR20190116416A (ko) 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
CN118340787A (zh) 药物
US20250325515A1 (en) Forms Of Aticaprant
TW202339732A (zh) 投予血紅素調節劑的方法
US20150335612A1 (en) Artemisinin And Its Derivatives For Use In The Treatment Of Kidney Disease
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
RU2855050C2 (ru) Способы введения модулятора гемоглобина
CN118369092A (zh) 施用血红蛋白调节剂的方法
TW202515579A (zh) 投予血紅素的調節劑之方法
HK40107036A (zh) 施用血红蛋白调节剂的方法
CN114652675A (zh) 一种盐酸乌拉地尔注射液的制备方法
JP2023537418A (ja) 慢性腎症を治療する方法及び医薬組成物
TWI802984B (zh) 一種含氮的飽和雜環化合物的應用
CA3161761A1 (en) Methods of administering voxelotor
US20190142786A1 (en) Methods of treating obesity in responder and non-responder populations
CN112569210A (zh) 一种吸入用马昔腾坦溶液及其制备方法
US20250312297A1 (en) Reduction of healthcare resource utilization by patients treated with intranasally-administered metoclopramide
WO2024173873A2 (en) Compounds, compositions, and methods for treating, ameliorating, and/or preventing pain
Standard PrMicafungin for Injection
US20250302777A1 (en) Methods for treating gastroparesis
CN117323320A (zh) 长链脂肪酸12-hht在睡眠呼吸暂停合并高血压中的应用
CN118955279A (zh) 一种(r)-4-(2-羟基-5-甲基苯基)-5-甲基己酸钙盐及其制备方法与应用
CN107362137A (zh) 一种含有甲磺酸多拉司琼的注射用组合物